Business Models and Strategy

 

HBI 2022: Panel sees a rosy future for ophthalmology

Ophthalmology continues to be a big area of investor interest, with considerable scope for consolidation in both healthcare services and also medical devices. As governments in the UK, Finland and parts of Eastern Europe in particular continue to increase outsourcing, the potential to unlock additional private pay services is increasing, and upselling of more complex lenses is on the rise. An expert panel convened at HBI 2022 to discuss the opportunities and challenges in the post-pandemic landscape.

HBI 2022: Dementia care clearly insufficient

The inexorable rise in the need for dementia care dominated the elderly care panel discussion at HBI 2022, whilst the global staffing crisis was also, inevitably, on the agenda. Is enough being done to prepare for the sharp rise in dementia patients expected in the coming years, and how are groups dealing with the war for talent? 

Interview, Philippe Salah, CEO Dental Monitoring

Philippe Salah tells HBI he likes to keep a low profile. His success with remote dental care group DentalMonitoring, which reached elusive $1bn unicorn status at the end of last year, is making that increasingly difficult. HBI chats to him to find out more about his business model, and his vision of the dental clinic of the future.

Rutherford Health to go into liquidation

The for-profit oncology group which holds roughly half the UK's proton beam capacity and has invested over £240m in capex is to go into liquidation, thanks to the pandemic and NHS indifference. In the UK just 1% of acute cancer patients get proton compared to 10% in Europe and 20% in the USA. What is likely to happen next?

Interview Nick West, Chief Medical Officer, Global Medical Affairs, Abbott Vascular 

Patients, particularly in Europe, the Middle East and Africa, have a very different view of how well their treatment went than the physicians who treat them and health care leaders who oversee healthcare delivery. Patients are frustrated from the earliest stages of their care journey, including symptom recognition and definitive disease diagnosis. We talk to Dr. Nick West, the Chief Medical Officer, Global Medical Affairs for Abbott’s Vascular business about the results from Beyond Intervention - a multi-year global research initiative that uncovers the differing perspectives of the patient, the physician, and the healthcare leader.

Kry laying off 10% of its staff

Stockholm-based digital health player Kry is laying off 10% of its 1,000-strong workforce to reassure its investors and its partners in trying times for the market.

Interview, Sneh Khemka, SimplyHealth

HBI speaks with Sneh Khemka, HBI 2022 panellist and CEO of UK-based cash plan group Simplyhealth, to hear why he thinks it is time for groups like his to step out of the shadows.

Exponential revenue growth fails to restore investor confidence in Babylon and Teladoc

Babylon and Teladoc, two of the world’s largest telehealth providers, have grown exponentially over the past few years, with Teladoc doubling its revenue and Babylon quadrupling its revenue in 2021. Q1 results show a continuation of this trend. Yet both group’s share prices have fallen around 90% over the past two years. We explore whether the market is right to be betting against these two expanding giants.

Find Us